| Literature DB >> 30301637 |
Vivien Hébert1, Claire Boulard2, Estelle Houivet3, Sophie Duvert Lehembre4, Luca Borradori5, Rocco Della Torre5, Claudio Feliciani6, Luca Fania7, Giovanna Zambruno8, Diana B Camaioni8, Biago Didona8, Branka Marinovic9, Enno Schmidt10, Nina Schumacher10, Christian Hünefeld11, Stefan Schanz11, Johannes Steffen Kern12, Silke Hofmann12, Anne Charlotte Bouyeure3, Catherine Picard-Dahan13, Catherine Prost-Squarcioni14, Frederic Caux14, Marina Alexandre14, Saskia Ingen-Housz-Oro15, Martine Bagot16, Emmanuelle Tancrede-Bohin16, Jean David Bouaziz16, Nathalie Franck17, Pierre Vabres18, Bruno Labeille19, Marie Aleth Richard20, Emmanuel Delaporte4, Alain Dupuy21, Michel D'Incan22, Gaelle Quereux23, François Skowro24, Carle Paul25, Cristina Bulai Livideanu25, Marie Beylot-Barry26, Marie Sylvie Doutre26, Martine Avenel-Audran27, Christophe Bedane28, Philippe Bernard29, Laurent Machet30, Hervé Maillard31, Denis Jullien32, Sebastien Debarbieux32, Bruno Sassolas33, Laurent Misery33, Claire Abasq33, Olivier Dereure34, Philippe Lagoutte3, Vincent Ferranti2, Victoria P Werth35, Dedee F Murrell36, Michael Hertl37, Jacques Benichou3, Pascal Joly2.
Abstract
The Pemphigus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity-Score (ABSIS) scores have been proposed to provide an objective measure of pemphigus activity. These scores have been evaluated only on already treated patients mainly with mild to moderate activity. The objective was to assess the interrater reliability of ABSIS and PDAI scores and their correlation with other severity markers in a large international study. Consecutive patients with newly diagnosed pemphigus were enrolled in 31 centers. Severity scores were recorded during a 24-month period by the same two blinded investigators. Serum was collected at each visit for ELISA measurement of anti-desmoglein antibodies. The intraclass correlation coefficient (ICC) and Spearman rank correlation coefficient were calculated. A total of 116 patients with pemphigus vulgaris (n = 84) or pemphigus foliaceus (n = 32) were included. At baseline, the ABSIS and PDAI ICCs were 0.90 (95% confidence interval [CI] = 0.85-0.93), and 0.91(95% CI = 0.87-0.94), respectively. The ICCs for PDAI were higher in moderate and extensive pemphigus (ICC = 0.82, 95% CI = 0.63-0.92 and ICC = 0.80, 95% CI = 0.62-0.90, respectively) than in patients with intermediate (significant) extent (ICC = 0.50, 95% CI = 0.27-0.68). Conversely, the ICCs for ABSIS were lower in patients with moderate extent (ICC = 0.44, 95% CI = 0.004-0.74) than in those with intermediate or extensive forms, (ICC = 0.69, 95% CI = 0.51-0.81 and ICC = 0.75, 95% CI = 0.51-0.88, respectively). During patients' follow-up, the ICCs of both ABSIS and PDAI scores remained higher than 0.70. ABSIS and PDAI skin (r = 0.71 and r = 0.75) but not mucosal (r = 0.32 and r = 0.37) subscores were correlated with the evolution of anti-DSG1 and anti-DSG3 ELISA values, respectively. ABSIS and PDAI scores are robust tools to accurately assess pemphigus activity.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30301637 DOI: 10.1016/j.jid.2018.04.042
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551